{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T17:00:14Z","timestamp":1702746014402},"reference-count":19,"publisher":"Universa BV","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2021,2,16]]},"abstract":"<jats:p>Background : Impact of antithrombotics on the fecal immunochemical test (FIT) for colorectal cancer (CRC) screening remains unclear.\n\nMethods : Patients undergoing colonoscopy for positive FIT in 2015 were assessed at 3 Belgian centers. Significant findings were advanced polyps (AP) (sessile serrated, tubular or villous adenomas &gt;1cm or high-grade dysplasia) and CRC. False positive FIT and detection of AP\/CRC with antithrombotics were calculated.\n\nResults : 510 patients (64% male, median (IQR) age 63.2 (60.2-66.4) years) were included. Colorectal pathology in 371\/510 (73%) was associated with male gender (70% vs. 48% ; p= .0001) and family history (16% vs. 8% ; p= .02). Antithrombotics in 125\/510 (25%) were associated with male gender (78% vs. 59% ; p= .0001), older age (65.2 (62.2-70.3) vs. 62.3 (58.7-66.3) years ; p= .0001) and GI-symptoms (18% vs. 11% ; p= .04). False positive FIT (25% vs. 28% ; p= .52) and detection of AP (42% vs. 36% ; p= .27) or\nCRC (6% vs. 5% ; p= .69) were similar in patients with vs. no antithrombotics. Use of antithrombotics did not predict a higher chance of colorectal pathology after adjusting for confounders.\n\nConclusion : Although antithrombotics were prescribed more frequently in male and older patients, detection of AP\/CRC was similar. Despite  increased GI symptoms, false positive FIT was similar with antithrombotics.<\/jats:p>","DOI":"10.51821\/84.1.349","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:46:26Z","timestamp":1620866786000},"page":"19-24","source":"Crossref","is-referenced-by-count":2,"title":["Impact of antithrombotics on the fecal immunochemical test for colorectal cancer screening : a multi-center Belgian experience"],"prefix":"10.51821","volume":"84","author":[{"given":"L.","family":"Wauters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.R.H.","family":"Van der Voort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Dobbels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Casneuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Vandervoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27062","published-online":{"date-parts":[[2021,2]]},"reference":[{"key":"ref0","unstructured":"Bevolkingsonderzoek Dikkedarmkanker. https:\/\/dikkedarmkanker.bevolkingsonderzoek.be\/"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"STOCK C, BRENNER H. Utilization of lower gastrointestinal endoscopy and fecal occult blood test in 11 European countries : evidence from the Survey of Health, Aging and Retirement in Europe. Endoscopy, 2017, 42(7) : 546-56.","DOI":"10.1055\/s-0029-1244127"},{"key":"ref2","unstructured":"STONESTREET J, CHANDRAPALAN S, WOOLLEY D, UTHMAN U, ARASARADNAM RP. Systematic Review and Meta-Analysis : Diagnostic Accuracy of Faecal Immunochemical Testing for Haemoglobin (FIT) in Detecting Colorectal Cancer for Both Symptomatic and Screening Population. Acta Gastroenterol. Belg., 2019, 82(2) : 291-9."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"LEVI Z, ROZEN P, HAZAZI R, VILKIN A, WAKED A, MAOZ E, et al. Sensitivity, but Not Specificity, of a Quantitative Immunochemical Fecal Occult Blood Test for Neoplasia Is Slightly Increased by the Use of Low-Dose Aspirin, NSAIDS, and Anticoagulants. Am. J. Gastroenterol., 2009, 104(4) : 933-8.","DOI":"10.1038\/ajg.2009.14"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"MANDELLI G, RADAELLI F, PAGGI S, TERRENI N, GOLA G, GRAMEGNA M, et al. Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening. Eur. J. Gastroenterol. Hepatol., 2011, 23(4) : 323-6.","DOI":"10.1097\/meg.0b013e3283438aac"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"TSUJI Y, GUNJI T, SATO H, ONO A, ITO T, OHATA K, et al. Antithrombotic drug does not affect the positive predictive value of an immunochemical fecal occult blood test. Dig. Endosc., 2014, 26(3) : 424-9.","DOI":"10.1111\/den.12208"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"BUJANDA L, SARASQUETA C, LANAS \u00c1, QUINTERO E, CUBIELLA J, HERNANDEZ V, et al. Effect of oral anticoagulants on the outcome of faecal immunochemical test. Br. J. Cancer, 2014, 110(5) : 1334-7.","DOI":"10.1038\/bjc.2014.38"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"BRENNER H, TAO S, HAUG U. Low-Dose Aspirin Use and Performance of Immunochemical Fecal Occult Blood Tests. JAMA, 2010, 304(22) : 2513.","DOI":"10.1001\/jama.2010.1773"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"HALLORAN SP, LAUNOY G, ZAPPA M. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition Faecal occult blood testing. Endoscopy, 2012, 44 : suppl. 3.","DOI":"10.1055\/s-0032-1309791"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"HEWITSON P, GLASZIOU P, WATSON E, TOWLER B, IRWIG L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult) : an update. Am. J. Gastroenterol., 2008, 103(6) : 1541-9.","DOI":"10.1111\/j.1572-0241.2008.01875.x"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"PARK D IL, RYU S, KIM Y-H, LEE S-H, LEE CK, EUN CS, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am. J. Gastroenterol., 2010, 105(9) : 2017-25.","DOI":"10.1038\/ajg.2010.179"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"SAWHNEY MS, MCDOUGALL H, NELSON DB, BOND JH. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010, 55(6) : 1637-42.","DOI":"10.1007\/s10620-010-1150-4"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"GANDHI S, NARULA N, GANDHI S, MARSHALL JK, FARKOUH ME. Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood tests? J Gastroenterol Hepatol 2013, 28(6) : 931-6.","DOI":"10.1111\/jgh.12201"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"CAMPBELL CL, SMYTH S, MONTALESCOT G, STEINHUBL SR. Aspirin Dose for the Prevention of Cardiovascular Disease. JAMA, 2007, 297(18) : 2018.","DOI":"10.1001\/jama.297.18.2018"},{"key":"ref14","unstructured":"VAN OVERBEKE L, ILEGEMS S, MERTENS G, MORTIER L, VAN DONGEN K, VERBEKE L, et al. Cold Snare Endoscopic Resection of Nonpedunculated Colorectal Polyps Larger Than 10 Mm. A Retrospective Series. Acta Gastroenterol. Belg., 2019, 82(4) : 475-8."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"IJSPEERT JEG, VERMEULEN L, MEIJER GA, DEKKER E. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat. Rev. Gastroenterol. Hepatol., 2015, 12(7) : 401-9.","DOI":"10.1038\/nrgastro.2015.73"},{"key":"ref16","unstructured":"COPPENS G, GEBOES K, DE LOOZE D, HINDRYCKX P, DE VOS M. Screeningsonderzoek naar darmkanker in vlaanderen met immunochemische fecaal-occultbloedtest. Tijdschr. Genees., 2016, 72(20) : 1169-75."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"VAN RIJN JC, REITSMA JB, STOKER J, BOSSUYT PM, VAN DEVENTER SJ, DEKKER E. Polyp miss rate determined by tandem colonoscopy : a systematic review. Am. J. Gastroenterol., 2006, 101(2) : 343-50.","DOI":"10.1111\/j.1572-0241.2006.00390.x"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"BRENNER H, HAUG U, HUNDT S. Sex Differences in Performance of Fecal Occult Blood Testing. Am. J. Gastroenterol., 2010, 105(11) : 2457-64.","DOI":"10.1038\/ajg.2010.301"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:46:33Z","timestamp":1620866793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/1872\/Impact%20of%20antithrombotics%20on%20the%20fecal%20immunochemical%20test%20for%20colorectal%20cancer%20screening%20:%20a%20multi-center%20Belgian%20experience\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2]]},"published-print":{"date-parts":[[2021,2,16]]}},"URL":"https:\/\/doi.org\/10.51821\/84.1.349","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}